Loading clinical trials...
Loading clinical trials...
A Phase I, Multicenter, Open Label, and Dose-Escalation Study of TT-01488, Administered Orally in Adult Patients With B-Cell Malignancies
Conditions
Interventions
TT-01488 Tablets
Locations
1
China
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
Start Date
March 30, 2023
Primary Completion Date
October 31, 2026
Completion Date
October 30, 2028
Last Updated
November 21, 2023
NCT07349849
NCT06590961
NCT05780034
NCT03050190
NCT03125577
NCT06351527
Lead Sponsor
TransThera Sciences (Nanjing), Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions